<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02719184</url>
  </required_header>
  <id_info>
    <org_study_id>352.2069</org_study_id>
    <nct_id>NCT02719184</nct_id>
  </id_info>
  <brief_title>Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease)</brief_title>
  <official_title>Observational Study in Healthy Subjects and Patients With COPD to Assess the Relationship Between Clinical, Imaging and Biomarker Measurements, and Progression of Emphysema Over Two Years [FOOTPRINTSâ„¢].</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The study will include 60 healthy subjects (ex-smoker without any airflow limitation), 125
      COPD GOLD (global initiative for chronic obstructive lung disease) I , 125 COPD GOLD II, 125
      COPD GOLD III and up to 20 patients with COPD and A1AT (Alpha1-Antitrypsin) deficiency (ZZ
      genotype). Soluble and imaging biomarkers will be investigated addressing different aspects
      of disease pathways postulated to be relevant for COPD progression.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 13, 2016</start_date>
  <completion_date type="Anticipated">March 8, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 8, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of exacerbations</measure>
    <time_frame>104 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of exacerbations</measure>
    <time_frame>104 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung function decline</measure>
    <time_frame>104 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of exacerbations</measure>
    <time_frame>104 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of lung density assessed by computed tomography scan</measure>
    <time_frame>104 weeks</time_frame>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">467</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <condition>Pulmonary Emphysema</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD GOLD I</arm_group_label>
    <description>Chronic obstructive pulmonary disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD GOLD II</arm_group_label>
    <description>Chronic obstructive pulmonary disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD GOLD III</arm_group_label>
    <description>Chronic obstructive pulmonary disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A1AT Deficiency</arm_group_label>
    <description>Alpha one anti-trypsin deficiency</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Solube and imaging biomarkers
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy volunteers and COPD patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General Inclusion Criteria

          -  Male or female healthy subjects or COPD (GOLD I to III) outpatients with or without
             A1AT deficiency

          -  Ex-smokers for at least 9 months with a smoking history of &gt;=20 pack years

          -  Signed informed consent consistent with ICH-GCP (International Conference on
             Harmonisation - Good Clinical Practice) guidelines prior to participation in the
             study, which includes the application of study restrictions

          -  Age &gt;= 40 and &lt;=70 years

          -  Body mass index (BMI) of &gt;= 18 and &lt;= 35 kg/m2 (&lt;= 30 kg/m2 in the MRI subset)

          -  Ability to perform all study related procedures including technically acceptable
             pulmonary function tests, body plethysmography, DLCO ( Diffusing Capacity of the lungs
             for Carbon Monoxide) , sputum induction (if applicable), chest CT (Computed
             Tomography) and MRI (if applicable)

        Inclusion Criteria Specific for Patients with COPD - Patients must have a current diagnosis
        of COPD made by a physician prior to or during Visit 1 and a mMRC (Modified Medical
        Research Council Dyspnea Scale) score of 1 or more. The diagnosis of COPD must be in
        accordance with GOLD Guidelines and must be documented by the following criteria: Known
        relatively stable airway obstruction with a post-bronchodilator FEV1 (Forced Expiratory
        Volume in first second)/FVC (Forced Vital Capacity) &lt; 70 %

          -  The current COPD must be mild, moderate or severe based on lung functions and symptoms
             and the clinical situation must have stabilized for at least 4 weeks prior to Visit 1.
             The following definitions adapted from the GOLD Guidelines apply:

               1. mild: post-broncho-dilator FEV1 &gt;=80% of predicted normal (GLI 2012 and JRS 2014)
                  at Visit 1

               2. moderate: 50%&lt;= post-broncho-dilator FEV1 &lt; 80% of predicted normal (GLI 2012 and
                  JRS 2014) without chronic respiratory failure at Visit 1

               3. severe: 30%&lt;= post-bronchodilator FEV1 &lt;50% of predicted normal (GLI 2012 and JRS
                  2014) without chronic respiratory failure at Visit 1

          -  Patients must be on stable therapy (not limited to respiratory medication) for the
             last 4 weeks prior to Visit 1

        Inclusion Criteria Specific Patients with COPD and A1AT Deficiency

        - Documented A1AT deficiency of ZZ genotype

        Inclusion Criteria Specific Healthy Subjects

          -  Normal lung function values at Visit 1 with a documented post-bronchodilator FEV1
             &gt;=80% of predicted normal (GLI 2012 and JRS 2014) and a post-bronchodilator FEV1/FVC
             &gt;= lower limit of normal

          -  Mean post DLCO over all acceptable measurements at Visit 1 of &gt;= 70% of predicted
             normal

          -  Further inclusion criteria apply

        Exclusion Criteria:

        General Exclusion Criteria

          -  Previous participation in this study or participation in another trial with an
             investigational drug within 6 weeks prior to Visit 1 or during the study

          -  Significant pulmonary disease or other significant medical conditions* (as determined
             by medical history, examination and clinical investigations at screening) that may in
             the opinion of the investigator result in any of the following:

               1. Put the subject at risk because of participation in the study

               2. Cause concern regarding the subject's ability to participate in this study *e.g.
                  rheumatoid arthritis, inflammatory bowel disease, severe liver disease,
                  psoriasis, hematological, infectious and psychiatric diseases

          -  Documented history of asthma. For allergic rhinitis or atopy, source documentation to
             verify that the subject does not have asthma

          -  Planned surgery during the study expected to interfere with study procedures and
             outcome

          -  Blood withdrawal of more than 100 mL within the past 6 weeks prior to Visit 1 and
             between Visit 1 and 2

          -  Significant alcohol or drug abuse within past 2 years prior to Visit 1

          -  Women who are pregnant, nursing or plan to become pregnant while in the study

          -  Place of permanent residence of less than 3 months prior to Visit 1

          -  For the MRI subset: subject who do not meet the following criteria for the MRI
             assessment at Visit 2: systolic blood pressure between 90 and 180 mmHg (SBP),
             diastolic blood pressure between 50 and 110 mmHg (DBP), pulse rate between 40 and 110
             bpm, ear temperature between 35 - 37.5 C, and a glomerular filtration rate (GFR) &gt;= 30
             mL/min (GFR must not be older than 14 days from the MRI assessment)

        Exclusion Criteria Specific for Patients with COPD

        - Respiratory tract infection or COPD exacerbation in the 4 weeks prior to Visit 1 or
        during the screening period prior to Visit 2, if rescheduling rules cannot be met

        Exclusion Criteria Specific Patients with COPD and A1AT Deficiency

          -  Newly added anti-inflammatory treatment within 4 weeks prior to Visit 1

          -  Patients on treatment with PDE (Phosphodiesterase)-5 inhibitors (e.g. Roflumilast) and
             maintenance treatment Methylxanthines (e.g. Theophylline)

          -  Hospitalisation for respiratory failure during the year prior to Visit 1

          -  A history of cystic fibrosis

          -  Clinical diagnosis of bronchiectasis requiring specific treatment

          -  Clinically relevant abnormal baseline hematology and blood chemistry

          -  Known active tuberculosis

          -  Patients with change in any therapy within 4 weeks prior to Visit 1

          -  Current and planned A1AT augmentation therapy

          -  A malignancy for which the patient has undergone resection, radiation or chemotherapy
             within past 5 years. Patients with treated basal cell carcinoma or fully cured
             squamous cell carcinoma are allowed

          -  Inability to comply with restrictions regarding diet, life style and medication

          -  Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostics Research Group</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brussels - UNIV St-Pierre</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerity of Alberta, Clinical Sciences Building</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUHC Glen Site</name>
      <address>
        <city>Montreal</city>
        <state>Migration Data</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster Univ. Medical Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4K1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IUCPQ (Laval University)</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gentofte University Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HYKS Keuhkosairauksien</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TYKS, Keuhkosairauksien klinikka, Turku</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IKF Pneumologie GmbH &amp; Co. KG</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH</name>
      <address>
        <city>GroÃŸhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fraunhofer ITEM</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KLB Gesundheitsforschung LÃ¼beck GmbH</name>
      <address>
        <city>LÃ¼beck</city>
        <zip>23552</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagoshima University Medical And Dental Hospital</name>
      <address>
        <city>Kagoshima, Kagoshima</city>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Showa University Fujigaoka Hospital</name>
      <address>
        <city>Kanagawa, Yokohama</city>
        <zip>227-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kishiwada City Hospital</name>
      <address>
        <city>Osaka, Kishiwada</city>
        <zip>596-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka, Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Showa University Hospital</name>
      <address>
        <city>Tokyo, Shinagawa-ku</city>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, St.Paul's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02559</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Medicine Centre, private prac., Bialystok</name>
      <address>
        <city>Bialystok</city>
        <zip>15044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Center, Gdansk</name>
      <address>
        <city>Gdansk</city>
        <zip>80 952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norbert Barlicki University Clinical Hospital No.1, Lodz</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Tuberculosis &amp; Lung Disease, Warsaw</name>
      <address>
        <city>Warsaw</city>
        <zip>01138</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital QuirÃ³nsalud Madrid</name>
      <address>
        <city>Pozuelo de AlarcÃ³n</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SkÃ¥nes universitetssjukhus, Lund</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2016</study_first_submitted>
  <study_first_submitted_qc>March 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2016</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

